Bio
Dr. Marshall Posner is a Professor of Medicine and Director of the Human Monoclonal Antibody Laboratory in the Department of Cell and Gene Therapy at Icahn School of Medicine at Mount Sinai. He is also Medical Director of the Head and Neck Oncology Center at the Mount Sinai Medical Center, and Medical Director of the Clinical Trials Office for the Tisch Cancer Institute in New York City, New York. Dr. Posner received his MD from Tufts University School of Medicine (1975), and completed his internship and residency in internal medicine at Boston City Hospital (1978) and a fellowship in medical oncology at the Dana-Farber Cancer Institute (1981). He was Medical Director of the Head and Neck Oncology Program and an Associate Professor of Medicine at the Dana-Farber Cancer Center and the Harvard Medical School (1994-2010) before joining Icahn School of Medicine at Mount Sinai and the Mount Sinai Medical Center. Dr. Posner has been an advocate for clinical research and multi-disciplinary care in h! ead and neck cancer. He has and continues to participate in international symposia and on planning committees devoted to advancing clinical care and directing clinical research in head and neck cancer.
He is a current or past member of the editorial boards of many journals, including the Journal of Clinical Oncology, American Journal of Clinical Oncology, Oral Oncology, The Oncologist, and Head and Neck, and he serves as an ad hoc reviewer for, among others, The New England Journal of Medicine, Cancer, Journal of Immunology, Clinical Cancer Research, Cancer Research, British Journal of Cancer, and Oncology. Dr. Posner has been a member of the National Institutes of Health Review Committees for the NIH Inter-Institute Program and the Specialized Programs of Research Excellence in Human Cancer, Head & Neck Cancer, and of the National Cancer Institute’s Special Emphasis Panel for phase II Contracts. He has published over 190 peer-reviewed basic laboratory and clinical studies, as well as multiple reviews and abstracts. He holds patents for Human Monoclonal Antibodies to viral and bacterial antigens.
Dr. Posner has been the principal investigator on numerous clinical and translational research trials as well as multiple phase 1 and 2 trials and NCI and NIAID funded research. He has been the Principal Investigator on International Phase III trials in head and neck cancer and has reported studies of antibody based immunotherapy in pemphigus and HIV, and adoptive immunotherapy in nasopharynx cancer.
He is a current or past member of the editorial boards of many journals, including the Journal of Clinical Oncology, American Journal of Clinical Oncology, Oral Oncology, The Oncologist, and Head and Neck, and he serves as an ad hoc reviewer for, among others, The New England Journal of Medicine, Cancer, Journal of Immunology, Clinical Cancer Research, Cancer Research, British Journal of Cancer, and Oncology. Dr. Posner has been a member of the National Institutes of Health Review Committees for the NIH Inter-Institute Program and the Specialized Programs of Research Excellence in Human Cancer, Head & Neck Cancer, and of the National Cancer Institute’s Special Emphasis Panel for phase II Contracts. He has published over 190 peer-reviewed basic laboratory and clinical studies, as well as multiple reviews and abstracts. He holds patents for Human Monoclonal Antibodies to viral and bacterial antigens.
Dr. Posner has been the principal investigator on numerous clinical and translational research trials as well as multiple phase 1 and 2 trials and NCI and NIAID funded research. He has been the Principal Investigator on International Phase III trials in head and neck cancer and has reported studies of antibody based immunotherapy in pemphigus and HIV, and adoptive immunotherapy in nasopharynx cancer.
